medigraphic.com
Instituto Nacional de Salud Pública

2008, Número 1

<< Anterior Siguiente >>

salud publica mex 2008; 50 (1)


Factores de riesgo de cáncer cervical en mujeres VPH positivas en México

Flores YN, Bishai DM, Shah KV, Lazcano-Ponce E, Lörincz A, Hernández M, Ferris D, Salmerón J

Idioma: Ingles.
Referencias bibliográficas: 44
Paginas: 49-58
Archivo PDF: 184.81 Kb.


RESUMEN

Objetivo. Identificar factores asociados con un mayor riesgo de desarrollar neoplasia intraepitelial cervical (NIC) de alto grado o cáncer en mujeres con virus de papiloma humano (VPH), en México. Material y métodos. Se utilizó un diseño de casos y controles. Un total de 94 casos y 501 controles fueron seleccionados de las 7 732 mujeres que participaron en el Estudio de VPH en Morelos, de mayo de 1999 a junio de 2000. La información sobre factores de riesgo se obtuvo de entrevistas y de los resultados de carga virales de VPH. Se estimaron razones de momios e intervalos de confianza de 95% con modelos multivariados de regresión no condicionada. Resultados. El incremento de edad, la carga viral elevada, la edad temprana al inicio de la vida sexual y el nivel socioeconómico bajo se asocian con un mayor riesgo de enfermedad en mujeres VPH positivas. Conclusiones. Estos resultados podrían tener implicaciones importantes a futuro para las actividades de tamizaje en México y en otros países de bajos recursos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Arrossi S, Sankaranarayanan R, Parkin DM. Incidence and mortality of cervical cancer in Latin America. Salud Publica Mex 2003;45:306-314.

  2. Bosch FX, Lörincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.

  3. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.

  4. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.

  5. Muñoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.

  6. Flores Y, Shah K, Lazcano E, Hernandez M, Bishai D, Ferris DG, Lorincz A, Hernandez P, Salmeron J; Morelos HPV Study Collaborators. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study. Salud Publica Mex 2002;44(4):335-344.

  7. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris D, Flores Y, Yunes E, Shah KV. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003;14(6):505-512.

  8. Collins SI, Mazloomzadeh S, Winter H, et al. Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study. Int J Cancer 2005;114:498-500.

  9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.

  10. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-1807.

  11. Hernandez-Giron C, Smith JS, Lörincz A, Lazcano E, Hernandez-Avila M, Salmeron J. High-Risk Human Papillomavirus Detection and Related Risk Factors Among Pregnant and Nonpregnant Women in Mexico. Sex Transm Dis 2005;32:613-618.

  12. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-1167.

  13. Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24S3:S1-S10.

  14. Smith EM, Johnson SR, Figueres EJ, et al. The frequency of human papillomavirus detection in postmenopausal women on hormonal replacement therapy. Gynecol Oncology 1997;65:441-446.

  15. Plummer M, Herrero R, Franceschi S et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control 2003;14:805-814.

  16. Castellsague X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20-28.

  17. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118:1481-1495.

  18. de Sanjose S, Bosch FX, Muñoz N, Shah K. Social differences in sexual behaviour and cervical cáncer. IARC Sci Publ 1997;138:309-317.

  19. Hernández Avila M, Lazcano Ponce EC, Alonso de Ruíz P, Romieu I. Evaluation of the cervical cancer screening program in Mexico: A population-based case-control study. Int J Epidemiol 1998;27:1-7.

  20. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papillomavirus 16 as a deteminant for development of cervical cancer in situ: a nested case-control study. Lancet 2000;355:2189-2193.

  21. Hernandez-Hernandez DM, Ornelas-Bernal L, Guido-Jimenez M, et al. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol 2003;90:310-317.

  22. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92:891-894.

  23. Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003;103: 519-524.

  24. Lörincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360: 228-229.

  25. Castle PE, Schiffman M, Scott DR, et al. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1311-1314.

  26. Shields TS, Brinton LA, Burk RD, et al. A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus. Cancer Epidemiol Biomarkers Prev 2004;13:1574-1582.

  27. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res 2005;166:277-297.

  28. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: Results from a population-based study in Costa Rica. Br J Cancer 2001;84:1219-1226.

  29. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-2104.

  30. Last J A. Dictionary of Epidemiology. Fourth Edition. Oxford University Press, New York. 2001.

  31. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370(9590):890-907.

  32. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007;110(1):87-95.

  33. Akers AY, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer. 2007;31(3):157-181.

  34. Schiffman M, Brinton L, Devesa S, Fraumeni J. Cervical cancer. In Cancer Epidemiology and Prevention, 2nd edition. Schottenfeld D, Fraumen JF, eds. Oxford University Press, New York. 1996.

  35. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Rodriguez AC, Burk RD. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007 Aug 23; [Epub ahead of print]

  36. Dalstein V, Riethmuller D, Prétet JL, Le Bail Carval K, Sautière JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C. Persistence and load of highrisk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106(3):396-403.

  37. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 83:1565-1572.

  38. Harris RWC, Briton LA, Cowdell RH, et al. Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer 1980;42:359-369.

  39. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodriguez AC, Bratti MC, Hildesheim A, Wacholder S, Long LR, Neve L, Pfeiffer R, Burk RD. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res. 2006;66(2):1218-1224.

  40. Rocha-Zavaleta L, Yescas G, Cruz RM, Cruz-Talonia F. Human papillomavirus infection and cervical ectopy. Int J Gynaecol Obstet. 2004;85(3):259-266.

  41. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer: an update. Drug Saf 2001;24:741-754.

  42. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control 2003;14:805-814.

  43. Santos C, Muñoz N, Klug S, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966-971.

  44. Gravitt PE, Burk RD, Lörincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;12:477-484.




2020     |     www.medigraphic.com